Načítá se...

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

BACKGROUND: Facial redness contributes to impaired psychosocial functioning in rosacea patients and the only approved treatment for erythema is topical brimonidine gel 0.33%. OBJECTIVES: To evaluate patient‐reported outcomes, as well as efficacy and safety, in subjects with self‐perceived severe ery...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	J Eur Acad Dermatol Venereol
Hlavní autoři:	Layton, A.M., Schaller, M., Homey, B., Hofmann, M.A., Bewley, A.P., Lehmann, P., Nohlgård, C., Sarwer, D.B., Kerrouche, N., Ma, Y.M.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	John Wiley and Sons Inc. 2015
Témata:	Original Articles
On-line přístup:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5054962/ https://ncbi.nlm.nih.gov/pubmed/26416154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.13305
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo otaguje tento záznam!

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

Podobné jednotky